Tiziana: Foralumab Drug Development Presses On With Additional EAP Enrollment
Fully human intranasal foralumab shows promise in treating Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS.
Targeted Oncology6h
FDA OKs Trial of Novel CAR T-Cell Therapy in T-ALL/LBL
The “off-the-shelf” CAR T-cell therapy CTD402 will be evaluated in a phase 1b/2 trial for patients with T-cell acute ...
Tiziana Life Sciences files IND application with FDA for ALS Phase 2 trial
Tiziana Life Sciences (TLSA) announced the submission of its Investigational New Drug, IND, application to the U.S. Food and Drug ...
The Manila Times2d
Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant.
Tiziana Life Sciences Ltd.: Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
NEW YORK, March 04, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully hu ...
Business Wire3h
Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany ...
(NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, today provided an update on its subsidiary, Adimune, Inc., (“Adimune”) ...
Vericel: Scalable Growth With Strong Margins
Vericel's FDA-approved regenerative medicine products and robust pipeline signal strong growth potential, with zero debt and ...
The Manila Times2d
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications
Proprietary Invisicare Delivery Technology Designed to Optimize Local Skin Penetration The proprietary Invisicare delivery technology, which Quoin has exclusive rights to for all orphan rare skin ...
EurekAlert!3d
Insilico Medicine and Tenacia Biotechnology announce research collaboration focused on CNS therapeutics discovery using generative AI
Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, and Tenacia Biotechnology (“Tenacia”), a commercial-stage biopharmaceutical ...